{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=13", "query": { "intervention": "antibody-drug conjugate", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T06:06:35.003Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03449030", "title": "A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies" ], "interventions": [ { "name": "TAK-164", "type": "DRUG" }, { "name": "89Zr-TAK-164", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2018-04-23", "completion_date": "2020-02-27", "has_results": true, "last_update_posted_date": "2021-03-22", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 4, "location_summary": "Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449030" }, { "nct_id": "NCT06764095", "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis and Ureter Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystectomy", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Local Therapy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ureterectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2025-01-08", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764095" }, { "nct_id": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "l-leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2023-12-13", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06219941" }, { "nct_id": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "M6223", "type": "DRUG" }, { "name": "NKTR-255", "type": "DRUG" }, { "name": "JB100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2022-08-17", "completion_date": "2027-01-22", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 8, "location_summary": "Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more", "locations": [ { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05327530" }, { "nct_id": "NCT01874054", "title": "Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-06", "completion_date": "2018-02-20", "has_results": true, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 13, "location_summary": "Birmingham, Alabama • San Francisco, California • Stanford, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874054" }, { "nct_id": "NCT07793994", "title": "Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "CNS Tumor", "Solid Tumor", "Relapsed Cancer", "Refractory Cancer", "Pediatric Cancer" ], "interventions": [ { "name": "Bulk RNA Sequencing", "type": "DIAGNOSTIC_TEST" }, { "name": "Immunohistochemistry (IHC)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 130, "start_date": "2026-09", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07793994" }, { "nct_id": "NCT05797168", "title": "Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Lung Adenocarcinoma", "Endometrial Cancer", "Lung Squamous Cell Carcinoma" ], "interventions": [ { "name": "Torvutatug samrotecan", "type": "DRUG" }, { "name": "Saruparib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Palacaparib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 622, "start_date": "2023-06-05", "completion_date": "2028-08-04", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05797168" }, { "nct_id": "NCT05527184", "title": "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "High Grade Serous Adenocarcinoma of Ovary", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cervical Cancer" ], "interventions": [ { "name": "IMGN151", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 256, "start_date": "2023-01-11", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05527184" }, { "nct_id": "NCT03364348", "title": "4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Utomilumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Ado-Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George W. Sledge Jr.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-10-30", "completion_date": "2022-02-14", "has_results": true, "last_update_posted_date": "2022-10-19", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03364348" }, { "nct_id": "NCT06014658", "title": "Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Antibody-Drug Conjugate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MBrace Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-11-07", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-15T06:06:35.003Z", "location_count": 17, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06014658" } ] }